Buprenorphine and Troleandomycin: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Troleandomycin
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Your body breaks down buprenorphine (your pain or opioid-treatment medicine) using a liver enzyme called CYP3A4. Troleandomycin is an antibiotic that slows that enzyme down. When the enzyme is slowed, buprenorphine clears out of your body more slowly, so more of it builds up.
More buprenorphine can mean stronger and longer opioid effects, like heavy drowsiness, feeling foggy, and in serious cases slowed breathing. The good news is your care team can manage this by adjusting your dose and watching you more closely. Please don't stop or change either medicine on your own. Just talk with your pharmacist or doctor so they can plan the safest approach.
Mechanism: Troleandomycin is a potent CYP3A4 inhibitor. Buprenorphine is metabolized primarily via CYP3A4 (it is not a prodrug), so inhibition reduces its clearance and increases plasma exposure (higher AUC/Cmax).
Effect / direction: Increased buprenorphine exposure, raising risk of prolonged opioid effects including sedation and respiratory depression. Evidence: probable. Onset: unspecified.
Management:
- If starting troleandomycin, consider reducing buprenorphine dose to stable effect; monitor frequently for sedation and respiratory depression.
- On stopping the inhibitor, consider a buprenorphine dose increase and monitor for withdrawal.
- For long-acting subQ formulations, use products allowing precise titration if adjustment is needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Because a CYP3A4 inhibitor can raise plasma buprenorphine concentrations, giving the two together may lead to extended opioid effects such as respiratory depression. When a patient on buprenorphine must also receive a CYP3A4 inhibitor, consider lowering the buprenorphine dose until stable drug effects are reached, and frequently watch for sedation and respiratory depression. Conversely, when a CYP3A4 inhibitor is stopped in a patient on buprenorphine therapy, consider raising the buprenorphine dose until stable drug effects are reached, and monitor for signs of opioid withdrawal2. If the dose cannot be adjusted once the CYP3A4 inhibitor is no longer present, switch the patient back to a buprenorphine formulation that allows finer dose adjustment. For patients being converted from transmucosal buprenorphine taken together with CYP3A4 inhibitors, confirm through monitoring that the plasma buprenorphine level achieved with subQ buprenorphine is sufficient. When a patient already receiving subQ buprenorphine needs a CYP3A4 inhibitor, watch for signs and symptoms of over-medication. Should signs and symptoms of buprenorphine toxicity or overdose develop and the concomitant drug cannot be reduced or stopped, lower the buprenorphine dose. If the available doses do not allow the target dose to be reached, stop treatment and manage the patient with a buprenorphine formulation that permits more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring.
Here's what your team typically does:
- They may lower your buprenorphine dose while you are on the antibiotic until your effects are stable, and watch you more closely for heavy drowsiness or slowed breathing.
- When the antibiotic is stopped, they may raise your buprenorphine dose back up and watch for withdrawal symptoms.
- If you use a long-acting shot form, they may switch you to a form that allows more precise dose changes.
Call your prescriber or pharmacist right away if you feel unusually sleepy, confused, or your breathing feels slow or shallow.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Whether concurrent use of CYP3A4 inhibitors alters buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, such interactions have been documented in studies that used transmucosal buprenorphine. Buprenorphine's effects may vary according to the route by which it is given 1.
Common questions
Can I take Buprenorphine and Troleandomycin together?
Troleandomycin can raise buprenorphine levels and increase the risk of excess sedation and slowed breathing. Don't change either drug yourself; your care team can adjust the buprenorphine dose and monitor you closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Troleandomycin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Troleandomycin interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring. Here's what your team typically does: They may lower your buprenorphine dose while you are on the antibiotic until your effects are stable, and watch you more closely for heavy drowsiness or slowed breathing. When the antibiotic is stopped, t… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Troleandomycin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Troleandomycin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist